Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
News provided by
Share this article
Share this article
BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed s Compensation Committee and made as a material inducement to each employee s entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on June 1, 2021 to purchase an aggregate 59,020 shares of Insmed common stock at an exercise price of $25.17 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
Message :
Required fields
BRIDGEWATER, N.J., June 4, 2021 /PRNewswire/ Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed s Compensation Committee and made as a material inducement to each employee s entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on June 1, 2021 to purchase an aggregate 59,020 shares of Insmed common stock at an exercise price of $25.17 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
Share this article
Share this article
NEW YORK, June 3, 2021 /PRNewswire/ TS Innovation Acquisitions Corp. (NASDAQ: TSIA), a special purpose acquisition company sponsored by an affiliate of leading global real estate developer, owner and investor Tishman Speyer, announced today that its stockholders have approved its business combination with Latch, Inc. (Latch), maker of the full-building enterprise software-as-a-service (SaaS) platform LatchOS.
At a special meeting of TSIA stockholders held today, approximately 98% of the votes cast, representing approximately 69% of TSIA s outstanding shares, approved the proposed business combination with Latch.
Following an anticipated closing on June 4, 2021, the combined company s common stock and warrants will be listed on the Nasdaq Global Select Market and will begin trading under the ticker symbols LTCH and LTCHW , respectively, on June 7, 2021. Latch expects to receive $453 million in cash, net of fees and expenses to be funded
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure
Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders
Objective response was observed in 60% of anti-PD-1 naïve patients and 50% of prior non-responders
Data suggest abscopal effect in some patients (i.e., reduction in non-injected non-irradiated lesions)
To date, the overall adverse event profile for the 16 injected patients has not differed from what is expected with radiotherapy or anti-PD-1 agents (head and neck cancer and non-small cell lung cancer primary tumors)
PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) $NBTX #NBTXNews Regulatory News:NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Bar.